Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Roche receives CE mark for Elecsys pTau181

September 2025—Roche has received the CE mark for its Elecsys pTau181 test to measure phosphorylated tau 181 protein, an indicator of amyloid pathology. The test, developed in collaboration with Eli Lilly, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer’s disease as the cause of cognitive decline.
The CE mark for the test was based on data from a prospective, multicenter study that included 787 patients in the United States, Europe, and Australia. The study showed the test was able to rule out Alzheimer’s disease with a high negative predictive value of 93.8 percent, based on a 22.5 percent prevalence of amyloid positivity according to PET scans, and with 83.6 percent sensitivity.

Cepheid gets Health Canada license for Xpert HIV-1 Viral Load XC

September 2025—Cepheid has received a medical device license from Health Canada for its Xpert HIV-1 Viral Load XC, a next-generation extended-coverage test intended to aid in assessing HIV viral load levels. The test is designed for use on the company’s GeneXpert systems.

ArteraAI Prostate gets breakthrough device designation

September 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer. ArteraAI Prostate analyzes digital pathology images of a patient’s prostate cancer biopsy slide to prognosticate long-term outcomes, such as 10-year risk of distant metastasis and prostate-cancer specific mortality, to help clinicians determine the most appropriate treatment option.

Bio-Rad launches four ddPCR platforms

September 2025—Bio-Rad Laboratories has launched four Droplet Digital PCR platforms, which include the company’s QX Continuum ddPCR system and the QX700 series of ddPCR platforms, acquired as part of Bio-Rad’s recent purchase of Stilla Technologies. The QX Continuum ddPCR system is designed for translational research applications and features a qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. The QX700 series consists of three ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, can process more than 700 samples per day, and include easy-to-use software for streamlined data interpretation.

Copan announces leadership transition in medical and scientific affairs

September 2025—Copan Diagnostics has appointed Hema Kapoor, MD, D(ABMM), as director of medical and scientific affairs for the Americas, succeeding Susan Sharp, PhD, D(ABMM), who will retire this month following more than three decades of distinguished service to clinical microbiology. Dr. Sharp joined Copan in 2018, after a career spanning more than 30 years as a clinical microbiologist, educator, and industry leader. She previously served as chief of microbiology at Kaiser Permanente and held leadership roles at the American Society for Microbiology, including chair of the committee on laboratory practices and past president. A diplomate of the American Board of Medical Microbiology and fellow of the American Academy of Microbiology, Dr. Sharp has been recognized with ASM’s highest clinical honor, the BioMérieux Sonnenwirth Award, and the ABMM Professional Recognition Award. At Copan, her leadership has been defined by keen insight and a steadfast advocacy for advancing microbiology.

Labcorp, NowDx collaborate to expand rapid syphilis testing

September 2025—Labcorp and NowDiagnostics are collaborating to expand access to rapid syphilis testing. The companies will distribute First to Know Syphilis Test kits at no cost to select community-based public health organizations across the United States. Labcorp and NowDx distributed kits to more than 15 organizations across the country, including to LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics. Labcorp serves as the exclusive commercial laboratory offering the test for health care providers as well as directly to consumers

Qiagen, Incyte to develop CDx for patients with myeloproliferative neoplasms

September 2025—Qiagen is collaborating with Incyte to develop a novel diagnostic panel to support Incyte’s portfolio of investigational therapies, including Incyte’s monoclonal antibody INCA033989, for patients with myeloproliferative neoplasms. Under the terms of the master collaboration agreement, Qiagen will develop a multi­modal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the Illumina NextSeq 550Dx.

Illumina launches TruSight Oncology 500 v2 research assay

September 2025—Illumina has launched TruSight Oncology 500 version 2, the next generation of the company’s flagship pancancer next-generation sequencing assay that enables in-house comprehensive genomic profiling from formalin-fixed, paraffin-embedded tissue for oncology research. A key enhancement of the new assay is fully integrated homologous recombination deficiency analysis included for every sample, powered by a gold-standard genomic instability scoring algorithm licensed from Myriad Genetics. Other updates include more sensitive variant calling and improved coverage of difficult genomic regions. The new kit has 50 percent less packaging and 70 percent fewer tubes.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

September 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East. Under the terms of the agreement, SehaMed will leverage its network of distributors across the Gulf Cooperation Council to introduce ColoHealth.

MRC Holland assay for Peutz-Jeghers gains EU IVDR certification

August 2025—MRC Holland announced that its Salsa MLPA Probemix P101 STK11 assay for the detection of Peutz-Jeghers syndrome received the CE mark for in vitro diagnostic use under IVDR regulation EU 2017/746. The probe mix detects copy number variations in the STK11 gene and has been updated with two improved and two newly added denaturation control probes that facilitate the detection of denaturation issues with exceptional sensitivity, according to a company press statement.

MARKETPLACE

TRENDING